Bioton-Indar deal

Publicly listed biotechnology company Bioton expects that the last condition currently blocking the purchase of 21.13% of the shares in Indar, Ukraine's largest insulin producer, from Cyprus-based Daveyton Consultants will be fulfilled by the end of this month. (Poland A.M.)